Roche and Bristol Myers partner on digital pathology algorithms

In the first project, Roche Digital Pathology is creating an artificial intelligence (AI)-based image analysis algorithm to help pathologists interpret the programmed death ligand Ventana 1 (SP142) market test. Bristol Myers Squibb will use this algorithm to generate biomarker data from clinical trial samples.

In the second project, Roche will build on its recently announced open-environment collaboration with PathAI to integrate an algorithm developed by PathAI for the analysis of differentiation group 8 (CD8) biomarkers into the Navify Digital Pathology workflow software. . The AI-powered algorithm will be used by Bristol Myers Squibb to analyze clinical trial samples that have been stained with Roche’s CD8 assay and generate quantitative spatial biomarker data.

Artificial intelligence-based pathology imaging tools can help support clinical trials in investigating targeted treatment options, Roche said in a press release.

“We believe that digital methods will bring significant improvements in the standardization and interpretation of tissue-based tests and enable wider access to tissue-based tests,” said Jill German, Head of Roche Diagnostics Pathology Customer Area. .

Ultimately, data from both projects will be used to aid in cancer diagnosis and advance personalized healthcare treatment options, with the goal of improving patient outcomes, she added.

Related reading

PathAI partners with Roche for AI technology
PathAI and Roche are partnering to develop and distribute PathAI’s artificial intelligence (AI)-based technology through Roche’s uPath enterprise software.

Copyright © 2022

Sharon D. Cole